Recent Research Analysts’ Ratings Updates for Zimmer Biomet (ZBH)
by Jessica Moore · The Cerbat GemA number of research firms have changed their ratings and price targets for Zimmer Biomet (NYSE: ZBH):
- 5/9/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
- 4/29/2026 – Zimmer Biomet was given a new $83.00 price target by Canaccord Genuity Group Inc..
- 4/29/2026 – Zimmer Biomet was given a new $92.00 price target by Robert W. Baird.
- 4/29/2026 – Zimmer Biomet had its price target lowered by Citigroup Inc. from $98.00 to $95.00. They now have a “neutral” rating on the stock.
- 4/29/2026 – Zimmer Biomet had its price target lowered by Barclays PLC from $100.00 to $94.00. They now have an “underweight” rating on the stock.
- 4/29/2026 – Zimmer Biomet had its price target lowered by JPMorgan Chase & Co. from $100.00 to $95.00. They now have a “neutral” rating on the stock.
- 4/29/2026 – Zimmer Biomet had its price target lowered by Citizens Jmp from $120.00 to $105.00. They now have a “market outperform” rating on the stock.
- 4/29/2026 – Zimmer Biomet had its price target lowered by Wells Fargo & Company from $98.00 to $90.00. They now have an “equal weight” rating on the stock.
- 4/29/2026 – Zimmer Biomet had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $92.00 price target on the stock, down from $98.00.
- 4/29/2026 – Zimmer Biomet had its price target lowered by Stifel Nicolaus from $110.00 to $105.00. They now have a “buy” rating on the stock.
- 4/19/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” to “hold”.
- 4/13/2026 – Zimmer Biomet is now covered by Leerink Partners. They set a “hold” rating and a $101.00 price target on the stock.
- 4/11/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
- 4/7/2026 – Zimmer Biomet was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
- 3/23/2026 – Zimmer Biomet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
- 3/23/2026 – Zimmer Biomet had its “neutral” rating reaffirmed by BTIG Research.
Zimmer Biomet Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.
Insider Transactions at Zimmer Biomet
In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.28% of the company’s stock.
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.